Patent · US Active

Use of escin

US9993512B2 · kind B2 · utility

0Cited by

10References

8Claims

0Family size

Assignee

MARINOMED BIOTECHNOLOGIE GmbH · AT

Inventors

Andreas Grassauer · Wien, AT
Eva Prieschl · Wien, AT

Key dates

Filing date	Sep 30, 2016
Grant date	Jun 12, 2018
Priority date	—
Expiry date	Sep 30, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.